Advertisement

U.S. markets open in 33 minutes

S&P Futures
4,080.25
-9.75(-0.24%)
Dow Futures
34,014.00
-142.00(-0.42%)
Nasdaq Futures
12,143.50
-8.50(-0.07%)
Russell 2000 Futures
1,936.90
-2.50(-0.13%)
Crude Oil
79.34
+0.47(+0.60%)
Gold
1,946.50
+1.20(+0.06%)

Advertisement

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Visitors trend2W10W9M

0.2700

+0.0006

(+0.22%)

At close: 04:00PM EST

0.2726

+0.00

(+0.96%)

Pre-Market:

08:53AM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	0.2694
Open	0.2788
Bid	0.0000 x 900
Ask	0.2800 x 800
Day's Range	0.2600 - 0.2788
52 Week Range	0.1750 - 15.2000
Volume	360,469
Avg. Volume	898,015

Market Cap	10.966M
Beta (5Y Monthly)	1.01
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGRX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Agile Therapeutics, Inc.
Daily – Vickers Top Insider Picks for 06/22/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Rating
Fair Value
Economic Moat
2 years agoArgus Research

Press Releases

GlobeNewswire
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline. Twirla Post-Marketing Studies As part of Twirla’s approval, the United States Food and Drug
GlobeNewswire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on February 6, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:0
- Magnolia Oil & Gas Increases Quarterly Dividend 15 Percent
  Business Wire
- Coastal Carolina Bancshares, Inc. Reports Record Fourth Quarter and Annual Earnings
  ACCESSWIRE
News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
By Johnny Rice, Benzinga